) | |
| Clinical data | |
|---|---|
| Trade names | Exoderil |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a688020 |
| ATC code | |
| Identifiers | |
IUPAC name
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C21H21N |
| Molar mass | 287.406 g·mol−1 |
| (verify) | |
Naftifine (brand name Exoderil) is an allylamine antifungal drug for the topical treatment of tinea pedis, tinea cruris, and tinea corporis (fungal infections).
Naftifine has triple action: antifungal, antibacterial and anti-inflammatory. Its precise mechanism of action is unknown, but may involve selectively blocking sterol biosynthesis via inhibition of the squalene 2,3-epoxidase enzyme.[1][2] The half-life is approximately 2–3 days.[2] The metabolites are excreted in the urine and feces.[3]
References
- ^ Robertson Dirk B, Maibach Howard I, "Chapter 61. Dermatologic Pharmacology" (Chapter). Bertram G. Katzung, Susan B. Masters, Anthony J. Trevor: Basic & Clinical Pharmacology, 11e: http://www.accesspharmacy.com/content.aspx?aID=4517257 Archived 2012-03-03 at the Wayback Machine.
- ^ a b Micromedex DRUGDEX Drug Point: Naftifine Hydrochloride. Accessed at www.thomsonhc.com/../BeginWith#secN10184 Archived 2019-12-17 at the Wayback Machine, February 18, 2010.
- ^ AccessPharmacy: Drug Monographs: Naftifine. Accessed at http://www.accesspharmacy.com/drugContentPopup.aspx?mid=6620§ion=10 Archived 2012-03-03 at the Wayback Machine, February 18, 2010.